Highlighting the three pillars of the REMaster™ drug discovery platform. Learn more about Remix science here: https://bit.ly/3QLHWK5
Remix Therapeutics
Biotechnology Research
Watertown, MA, MA 6,027 followers
Reprogramming RNA Processing, Designing Therapeutic Solutions
About us
Remix launched in 2020 with a vision to transform patient's lives through modulation of RNA processing. Our breakthrough science provides a path to identify small molecules that impact the expression of disease driving mRNAs and proteins. We take on the challenge of addressing drug targets in diseases of high unmet medical need to bring new therapeutic options to patients. Remix has a commitment to demonstrate the highest levels of scientific integrity with urgency because those patients are counting on us to deliver. With an in-house technology platform built from scratch, we have rapidly generated multiple drug discovery programs that are advancing towards the clinic.
- Website
-
https://www.remixtx.com
External link for Remix Therapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Watertown, MA, MA
- Type
- Privately Held
- Founded
- 2018
Locations
-
Primary
Get directions
100 Forge Rd
Watertown, MA, MA 02472, US
Employees at Remix Therapeutics
Updates
-
We are excited to announce that Remix has achieved a milestone in our collaboration with Roche! View the press release here: https://bit.ly/4cR6JFi
-
-
Meet Shreya Basireddy, who joins us as a co-op from Northeastern University with a degree in Bioengineering with minors in both Computer Science and Film Production. We can't wait to see Shreya's contributions this semester!
-
-
Our Spanish Tapas themed happy hour was un-bull-ievably fun, complete with a delicious spread of snacks, homemade sangria, videos of Spain's famous sights, and traditional Spanish flamenco music! 💃🍷🐂#RemixingTogether
-
-
Introducing Alexander Ivliev, our newest #Remixer! Alex brings a wealth of experience in translational computational biology to our bioinformatics and data science team and will be working on clinical and pre-clinical programs. Welcome to the team!
-
-
Delighted to welcome our newest board member Maria Koehler MD PhD. Maria brings extensive drug development experience to our board and we look forward to partnering with her as we progress our pre-clinical and clinical programs. Read the press release here: https://bit.ly/3xmTqgH
-
-
Highlighting key takeaways from the Remix poster on REM-422 in AML at the European Hematology Association (EHA) meeting last week!
-
Remix CEO Peter Smith will be discussing company progress at the UBS Biotech Management Live fireside chat later this morning.
-
-
Delighted for Remix to share our exciting REM-422 pre-clinical AML data at EHA!
We're excited to announce that Remix Head of Biology, Charles Kung, will share the latest data emerging from our labs showing our first-in-class MYB mRNA degrader with broad activity across pre-clinical models of myeloid malignancies at European Hematology Association (EHA) tomorrow at 6pm CEST. View full press release here: https://bit.ly/3KNvoOV
-
-
We're excited to announce that Remix Head of Biology, Charles Kung, will share the latest data emerging from our labs showing our first-in-class MYB mRNA degrader with broad activity across pre-clinical models of myeloid malignancies at European Hematology Association (EHA) tomorrow at 6pm CEST. View full press release here: https://bit.ly/3KNvoOV
-